Partnership Opportunities
Partnership Opportunities
Partnering with Xetley
Global Commercial and Development Partners: XETLEY is actively seeking innovative partnerships to collaborate on developing and commercializing new therapies that can fulfill unmet medical needs in Latin America. We welcome the opportunity to learn about emerging new drug discovery and technology-enabling solutions for patient care. XETLEY has extensive experience in market access strategies, regulatory requirements and commercial opportunities. We work with partners to determine areas of common interest that can be financially rewarding, while building long-lasting relationships.
To learn more about our capabilities and opportunities for partnership, please contact us.
International Business
In recent years, XETLEY has placed emphasis on the commercialization and international expansion of its vast product portfolio of specialty drugs to new Latin American markets. Through our collaboration with a network of local distribution channels and partnering with reputable manufacturers through licensing and co-development of products, XETLEY has experienced an extraordinary growth and positioned itself as an important specialty pharmaceutical organization. Our keys to success lie in our capacity to adapt to the ever-changing market dynamics and our ability to uncover opportunities not so apparent at plain sight. We believe to have mastered the balance of bringing to market cost-conscious innovative therapies while bringing excellent value to our partners and stakeholders.
Uruguay
Xetley Uruguay is a Uruguayan Company specialized in the distribution and commercialization of Biologicals Products and Pharmaceuticals Specialties in the southern cone markets. Its geographical location, financial openness and a solid banking platform makes Uruguay a strategic location to access many neighboring markets in the region for our vast portfolio of specialty products.
Brazil
Xetley Brazil Is located in the major city of Sao Paolo, one of the largest cities in Brazil. This entity can cover the vast market of Brazil with some products in the private market as well as the public market. Government tenders emergency spot sales and acquisition by judicial demands of highly specialized products are the focus in this market. In Brazil, we also conduct market development and market intelligence services for our partners and actively procure opportunities for technology transfer of selected drugs to government’s biopharmaceutical entities.
Venezuela
Xetley Venezuela is a company established specifically to deal with the complexities and demands of the Venezuelan market. Its business is primarily focused on government tenders and institutional sales, while participating in the private market through the collaboration of distributors and wholesalers. Our core specialties in this market consist of biologicals, hemato-oncology, immunotherapies, HIV, orphan drugs and renal products. Xetley Venezuela houses one of the largest infrastructures of the group from where many of the region’s regulatory, legal and marketing operations are carried out.
Dominican Republic
Xetley Dominican is our Caribbean hub, which handles operations within the Dominican Republic and other neighboring Islands. Its core markets are primarily the participation in public tenders, direct government sales and the private market. We have a unique portfolio of hemato-oncology drugs, biologicals, immunotherapies, HIV and renal products. Additionally, we are involved in the registration of two innovative therapies in an effort to satisfy existing unmet medical needs. It is one of the fastest growing subsidiaries thanks to the collaboration with our partners and the existence of a “simplified” regulatory approval process for drugs originating from jurisdictions of high regulatory vigilance.
United States
Our presence in the U.S. is through our subsidiary company in Florida, dedicated to the commercialization of medical devices and specialty supplements for chronic diseases. The U.S. remains the largest medical device market in the world, with a market size of around $156 billion, and it represented about 40 percent of the global medical device market in 2017 (www.selectusa.gov). We believe there are clear opportunities for unique and innovative devices that can grab the attention of key retailers and/or the end consumers. We are developing several medical and health-related mobile apps in areas where few players have made any significant in-roads.
Our Team
Convallis ullamcorper aliquet ultrices orci cum vestibulum lobortis erat.
Changing lives one patient at time!